AIDX — 20/20 Biolabs Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual balance sheet for 20/20 Biolabs, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Cash and Short Term Investments	3.35	8.81	4.09	1.78	1.03
Net Total Accounts Receivable
Net Total Receivables	4.22	0.765	0.069	0.135	0.2
Total Inventory
Prepaid Expenses
Total Current Assets	7.94	9.73	4.3	2.03	1.47
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	1.68	1.67	1.18	0.889	0.662
Net Intangible Assets
Long Term Notes Receivable
Other Long Term Assets
Total Assets	10.3	12.2	6.37	3.58	4.14
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	2.25	1.63	1.01	1.36	2.46
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	3.38	2.84	2.08	2.08	4.16
Redeemable Preferred Stock
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	6.89	9.37	4.29	1.51	-0.019
Total Liabilities & Shareholders' Equity	10.3	12.2	6.37	3.58	4.14
Total Common Shares Outstanding